Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.

Journal:

Journal of Clinical Oncology

Published:

2025-05-24

DOI:

10.1200/jco.24.01119

Affiliations:

19

Authors:

19

Go to article

Institutions	Authors	Share
The University of Osaka Hospital, UOsaka, Japan	1.500000	0.08
Tohoku University Hospital, Japan	1.500000	0.08
Kansai Medical University Hospital, Japan	1.000000	0.05
Osaka Rosai Hospital, Japan	1.000000	0.05
Higashiosaka City Medical Center, Japan	1.000000	0.05
IMSUT Hospital, UTokyo, Japan	1.000000	0.05
Kobe City Medical Center General Hospital, Japan	1.000000	0.05
Kushiro Rosai Hospital, Japan	1.000000	0.05
Saitama Cancer Center, Japan	1.000000	0.05
Yokohama Municipal Citizen's Hospital, Japan	1.000000	0.05
Aichi Cancer Center Hospital, Japan	1.000000	0.05
Nagoya Medical Center, Japan	1.000000	0.05
National Hospital Organization Osaka National Hospital, Japan	1.000000	0.05
Wakayama Medical University, Japan	1.000000	0.05
Osaki Citizen Hospital, Japan	1.000000	0.05
Chiba Cancer Center, Japan	1.000000	0.05
Shizuoka Cancer Center, Japan	1.000000	0.05
Osaka International Cancer Institute, Japan	0.500000	0.03
Kindai University, Japan	0.500000	0.03

Interested in Oncology and Carcinogenesis?